ImmuCell (NASDAQ: ICCC) — Perfil da empresa, notícias e dados financeiros
ImmuCell develops products for animal health, particularly focusing on mastitis solutions in the dairy and beef industries.
ImmuCell
ImmuCell (NASDAQ:ICCC) focuses on developing and producing products that improve animal health and productivity in the dairy and beef industries. Known for its innovative approach, the company mainly operates within the bovine health sector, striving to provide effective solutions for mastitis, one of the most costly diseases affecting dairy cows. Among its flagship projects is First Defense®, a unique product designed to prevent this disease in newborn calves, showcasing ImmuCell's dedication to enhancing immune responses without relying on antibiotics. With a strong belief in sustainable and responsible animal care, ImmuCell’s objectives include continuing to expand its product line, improving farm profitability and animal welfare, and addressing the pressing issue of antibiotic resistance in agriculture.
Resumo
Operações
Produtos e/ou serviços de ImmuCell
- First Defense, a non-antibiotic preventative for scours in calves, providing immediate immunity against E. coli, coronavirus, and rotavirus.
- California Mastitis Test (CMT), a somatic cell count test that helps dairy producers manage udder health and milk quality.
- Tri-Shield First Defense, an extension of the First Defense line, offering broader protection against scours in calves.
- Purishield line of products, designed to protect animals from environmental pathogens.
- Dual-Force First Defense, combining the benefits of immediate immunity against pathogens that cause scours with technology to support gut health.
equipe executiva do ImmuCell
- Paul F. Olivier Te BoekhorstPresident, CEO & Director
- Timothy C. FioriCFO, Secretary & Treasurer
- Bobbi Jo BrockmannSenior Vice President of Sales & Marketing
- Elizabeth S. ToothakerDirector of Finance & Administration and Controller
- A. Gustavo ScaffaSenior Director of Quality
- John W. ZinckgrafDirector of Product Development
Principais indicadores financeiros
Resultados divulgados pela ImmuCell , em USD.
- Cap. de mercado
- 96,5 mi
- Receita (TTM)
- 30,7 mi
- P/L
- 151.7
- LPA (diluído, TTM)
- 0.1
- Dividend yield
- —
- Margem de lucro
- 2.6%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 27,6 mi | 1,6 mi | -1 mi | |
| 26,5 mi | -1,6 mi | -2,2 mi | |
| 17,5 mi | -5,7 mi | -5,8 mi | |
| 18,6 mi | -2,3 mi | -2,5 mi |